Eden Research plc · LSE:EDEN
Eden Research — Proactive Investors One2One Forum (February 2019)
29 slides from Eden Research's conference presentation, February 2019
Slide 1: Proactive Investors One2One Forum
P ROAC T I V E I N V E S TO R S O N E 2 O N E F O R U M SEAN SMITH, CEO | A L E X A B R E Y, C F O
Slide 2: Introduction to Eden Research
INTRODUCTION TO EDEN RESEARCH 2
Slide 3: Eden Research: AIM listed since 2012, market cap £20m
LON:EDEN AIM listed since 2012 Market cap £20m Eden Research We have intellectual property provides sustainable and expertise in plant-derived solutions for challenges sustainable chemistry, in three key industries: microencapsulation and formulation technologies. 3
Slide 4: Management and Chairman
SEAN SMITH CHIEF EXECUTIVE OFFICER Over 25 years experience in the speciality chemicals and industrial biotechnology industries LY K E L E VA N D E R B R O E K NON-EXECUTIVE CHAIRMAN Formerly Board member of Bayer CropScience and President of Bayer Animal Health, both divisions of Bayer AG ALEX ABRE
Slide 5: Sustaine encapsulation technology
ACTIVE INGREDIENT ENCAPSULATED PAYLOAD Particles are derived from natural yeast cells. STABILISED AQUEOUS EMULSION Sustaine encapsulates active ingredients and provides for the sustained release of these ingredients enabling their safe, more PAYLOAD RELEASE ON CONTACT WITH WATER efficient use. AS PA
Slide 6: Sustaine: cost effective, versatile delivery system
CO S T E F F E C T I V E U S E F U L AC R O S S A W I D E R A N G E O F AC T I V E INGREDIENTS A H I G H C A PAC I T Y D E L I V E R Y S YS T E M Particles are derived from natural yeast cells. V E R S AT I L E A N D R O B U S T Sustaine encapsulates active ingredients and N AT U R A L A N D provide
Slide 7: Partnerships across three key industries
We work globally through multi-national and local partnerships to develop and launch solutions for challenges facing three key industries. C R O P P R OT E C T I O N A N I M A L H E A LT H CONSUMER PRODUCTS Foliar disease & insect control Shampoos Head-lice treatment Open field & greenhouses Conditi
Slide 8: Challenges facing conventional crop protection products
Conventional crop protection products face major challenges such as: The global crop protection The biopesticide market is market is valued at approx. projected to reach Neonicotinoid insecticides Conventional crop protection were worth $3.1 billion products formulated with globally but are now faci
Slide 9: Regulatory pressure on conventional pesticides
The dominant molluscicide approved for use in the EU is metaldehyde. The UK banned metaldehyde in 2018. The re-registration of copper-based products as fungicides was approved in the EU but a New EU rules have prohibited any substance identified as an Endocrine Disruptor from being used in plant pro
Slide 10: Focus on crop protection products
Our focus is on crop protection, developing products based on sustainable chemistries to protect high-value crops from pests and disease, with equal or better performance when compared with conventional pesticides. FUNGICIDES NEMATICIDES INSECTICIDES MOLLUSCICIDES PRODUCTS Botrytis, powdery Root kno
Slide 11: Terpene-based biopesticides formulated with Sustaine
Our products harness the biocidal activity of naturally occurring molecules produced by plants as part of their defence systems. These active ingredients are known as terpenes. Our biopesticides, formulated with Sustaine, add value compared to conventional pesticides by: Naturally binding to plant a
Slide 12: Commercial partners across 5 continents
We now have commercial partners in place across 5 continents 12
Slide 13: £13m invested in IP and registrations
£13m 11 10 invested in IP countries have granted new local & registrations product authorisation distributorships in 2018 130 29 44 granted and countries with pending countries with IP pending patents registration applications protection 13
Slide 14: Product sales commenced for Mevalone
Product sales have commenced in key markets where we have authorization to market and sell our first product, Mevalone 14
Slide 15: Regulatory clearance for first product
Eden Research has regulatory clearance for its first product in multiple countries with approval expected for its second product in 2019 15
Slide 16: Achieving our vision
ACHIEVING OUR VISION 16
Slide 17: Vision: leader in sustainable bioactive products
Our vision is to be the leader in sustainable bioactive products enabled or enhanced by our novel encapsulation and delivery technologies 17
Slide 18: Significant market potential
UNIQUE CLEAR COMMERCIAL SKILLED AND EXPERIENCED TRAJECTORY OF TECHNOLOGY PROGRESS PROFESSIONALS FINANCIAL GROWTH SIGNIFICANT MARKET POTENTIAL ▪ The global biopesticides market is projected to be worth more than ▪ The biopesticides market is growing at a CAGR of approximately ▪ Animal health market v
Slide 19: Significant market potential: pressure on conventional pesticides
UNIQUE CLEAR COMMERCIAL SKILLED AND EXPERIENCED TRAJECTORY OF TECHNOLOGY PROGRESS PROFESSIONALS FINANCIAL GROWTH SIGNIFICANT MARKET POTENTIAL ▪ Ongoing pressure on the conventional ▪ Significantly lower costs of bringing biopesticides pesticides market, which is subject to to market – around increas
Slide 20: Unique technology
SIGNIFICANT MARKET CLEAR COMMERCIAL SKILLED AND EXPERIENCED TRAJECTORY OF POTENTIAL PROGRESS PROFESSIONALS FINANCIAL GROWTH UNIQUE TECHNOLOGY ▪ encapsulation technology without ▪ Significant investment in patent limitations such as residue limits, pest protection and the registration of new resistan
Slide 21: Clear commercial progress: pipeline
SIGNIFICANT MARKET UNIQUE SKILLED AND EXPERIENCED TRAJECTORY OF POTENTIAL TECHNOLOGY PROFESSIONALS FINANCIAL GROWTH CLEAR COMMERCIAL PROGRESS ▪ Solid commercial pipeline ▪ ▪ with ▪ applications pending in 29 in new countries the next three years ▪ Commercial ▪ and collaborative relationships with st
Slide 22: Clear commercial progress: approvals and distributors
SIGNIFICANT MARKET UNIQUE SKILLED AND EXPERIENCED TRAJECTORY OF POTENTIAL TECHNOLOGY PROFESSIONALS FINANCIAL GROWTH CLEAR COMMERCIAL PROGRESS for the supporting label extensions regulatory approval of on crops and the active ingredients and authorisation in Central (“Sipcam”) appointed Europe for th
Slide 23: Skilled and experienced professionals
SIGNIFICANT MARKET UNIQUE CLEAR COMMERCIAL TRAJECTORY OF POTENTIAL TECHNOLOGY PROGRESS FINANCIAL GROWTH SKILLED AND EXPERIENCED PROFESSIONALS Wealth of experience in the and appointed sectors globally as Non-Executive Director and Chairman – former Board member and COO of Bayer to maintain a CropSci
Slide 24: Trajectory of financial growth
SIGNIFICANT MARKET UNIQUE CLEAR COMMERCIAL SKILLED AND EXPERIENCED POTENTIAL TECHNOLOGY PROGRESS PROFESSIONALS TRAJECTORY OF FINANCIAL GROWTH and from product sales by key partners 24
Slide 25: Trajectory of financial growth: 2018 results
SIGNIFICANT MARKET UNIQUE CLEAR COMMERCIAL SKILLED AND EXPERIENCED POTENTIAL TECHNOLOGY PROGRESS PROFESSIONALS TRAJECTORY OF FINANCIAL GROWTH Revenue Upfront and Operating profit* milestone payments (2017: £1.9m) (2017: loss £0.6m) (2017: £1.1m) Product sales Operating loss Net cash increased 112% (
Slide 26: What next?
WHATIN EXT? J * Y
Slide 27: Upcoming priorities and launches
▪ Regulatory clearance in ▪ Bayer Animal Health commercial new countries launches ▪ Revenue growth ▪ TerpeneTech product launches ▪ Partnerships for Mevalone ▪ Pursue opportunities in the seed in new territories treatments market ▪ Pursue collaboration with majors ▪ Expand crops and diseases treated
Slide 28: Scope for further exploitation of core technologies
Significant scope for further Strong potential for Eden Research’s exploitation of the Company’s current and pipeline products across core technologies beyond a broad segment of the crop biopesticides and crop protection industry with new crop protection and disease targets under active evaluation B
Slide 29: Thank you
T H A N K YO U
Eden Research — Proactive Investors One2One Forum (February 2019) on 6ix